会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • SUBCUTANEOUS IMPLANTS BASED ON NOMEGESTROL DERIVATIVES
    • 基于NOMEGESTROL衍生物的不足植入物
    • WO1994006437A1
    • 1994-03-31
    • PCT/FR1993000900
    • 1993-09-17
    • LABORATOIRE THERAMEX S.A.LANQUETIN, MichelTHOMAS, Jean, LouisPARIS, JacquesCOUTINHO, Elsimar
    • LABORATOIRE THERAMEX S.A.
    • A61K31/57
    • A61K31/57
    • The present invention relates to the field of therapeutical chemistry and more particularly to pharmacotechny. Specially, the present invention relates to new compositions adapted to local administration and more precisely to forms intended to be placed in the subcutaneous tissues and commonly called implants. Said implants are of various natures (hydrophobic, hydrophilic, biodegradable) and of various types (reservoir, matrix). Said implants incorporate an efficient dose of a derivative of 3,20-dioxo 6-methyl 17(alpha)-acetoxy 19-nor pregna 4,6-diene optionally substituted in the 3 and/or 17(alpha) position, associated or mixed with a biologically acceptable inert excipient. The implants thus obtained are efficient contraceptive agents having an active duration of a least one year with minimum secondary effects.
    • 本发明涉及治疗化学领域,更具体地涉及药理学技术领域。 特别地,本发明涉及适于局部施用的新组合物,更准确地说涉及旨在放置在皮下组织和通常称为植入物中的形式。 所述植入物具有各种性质(疏水性,亲水性,生物降解性)和各种类型(储层,基质)。 所述植入物掺入有效剂量的3,20-二氧代6-甲基17(α) - 乙酰氧基19-去甲前na 4,6-二烯衍生物,其在3和/或17(α)位置任选取代,相关联或混合 具有生物学上可接受的惰性赋形剂。 如此获得的植入物是具有至少一年的活性持续时间并且具有最小次要效果的有效的避孕药。
    • 4. 发明申请
    • HORMONAL COMPOSITION CONSISTING OF AN OESTROGEN COMPOUND AND OF A PROGESTATIONAL COMPOUND
    • 雌激素化合物和孕激素组合物的组成
    • WO1998015279A1
    • 1998-04-16
    • PCT/FR1997001792
    • 1997-10-08
    • LABORATOIRE THERAMEXLANQUETIN, MichelPARIS, JacquesTHOMAS, Jean-Louis
    • LABORATOIRE THERAMEX
    • A61K31/57
    • A61K45/06A61K31/56A61K31/565A61K31/57Y10S424/811Y10S514/841Y10S514/843A61K2300/00
    • The invention concerns the field of chemical therapy and more particularly the field of pharmaceutical hormonal technique. More precisely it concerns novel pharmaceutical hormonal compositions characterised in that they are formed by an oestroprogestational combination consisting of an oestrogen compound and a progestational compound, associated or mixed with one or several non-toxic, inert and pharmaceutically acceptable excipients, for oral administration. The invention also concerns the use of the oestroprogestational mixture in which the oestrogenic constituent and the progestational constituent are administered in combination. The combined association can be prescribed continuously or intermittently, for producing a composition for treating oestrogenic deficiencies, preventing osteoporosis and cardiovascular diseases in the menopausal woman, or still for blocking ovulation in a woman during the period of ovarian activity. The invention also concerns a method for preparing these novel pharmaceutical oestroprogestational compositions.
    • 本发明涉及化学治疗领域,更具体地涉及药物激素技术领域。 更确切地说,它涉及新型药物激素组合物,其特征在于它们由与雌激素化合物和促孕化合物组成的产卵组合形成,其与一种或多种无毒,惰性和药学上可接受的赋形剂相关或混合,用于口服给药。 本发明还涉及其中雌激素成分和促孕成分组合施用的产卵药混合物的用途。 可以连续或间歇地规定组合关联,用于生产用于治疗雌激素缺乏症,预防绝经妇女的骨质疏松症和心血管疾病的组合物,或仍然在卵巢活动期间阻止女性排卵。 本发明还涉及制备这些新型药物产卵药组合物的方法。